IP Library Granted Patent US 11,083,694
Granted Patent B2
US 11,083,694 · App. 17/160,951 · Granted Aug 10, 2021

Injectable phenol formulations and methods of their use

Inventors: Leonard O'Mahony (Westmeath, IE); Sharon Hamm (Odessa, FL); John Devane (Dublin, IE); Imran Ahmed (Wilmington, NC); David Penake (Atlanta, GA)
Assignee: SAOL INTERNATIONAL DEVELOPMENT LTD.
A61K31/05A61K9/0014A61K9/0019A61K47/40A61P23/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,083,694
App. No.
17/160,951
Granted
Aug 10, 2021
Kind
B2
Abstract

Phenol formulations including phenol and an encapsulation agent, such as a cyclodextrin or derivatives thereof, and uses of such formulations.

Claims (35)

1. A method for creating a nerve-block in a mammal comprising:

administering an effective amount of a phenol formulation, the formulation consisting of phenol,

a cyclodextrin or derivative thereof complexing at least a portion of the phenol,

at least one pharmacologically acceptable solvent for administration,

at least one dye or other agent to provide for visual localization of the phenol formulation, and

optionally one or more pharmaceutically acceptable excipients.

2. The method according to claim 1 , wherein the administering is by injection.

3. The method according to claim 1 , wherein the administering is by topical application.

4. The method according to claim 1 , wherein the cyclodextrin is hydroxypropyl-β-cyclodextrin (HP-β-CD).

5. The method according to claim 4 , wherein the concentration of the hydroxypropyl-β-cyclodextrin in the formulation is from about 10% to about 20% by weight (w/w) of the formulation.

6. The method according to claim 5 , wherein the concentration of the hydroxypropyl-β-cyclodextrin is from about 12% to about 18% by weight (w/w) of the formulation.

7. The method according to claim 6 , wherein the concentration of the phenol in the formulation is from about 3% to about 9% by weight (w/w) of the formulation.

8. The method according to claim 7 , wherein the concentration of the phenol is about 6% by weight (w/w) of the formulation.

9. The method according to claim 1 , the method further comprising visualizing the phenol formulation.

10. The method according to claim 9 , wherein the visualizing is performed by ultrasound, electronic stimulation, fluoroscopy, or camera.

11. A method for treating therapeutic, cosmetic, or tissue lysis condition in a patient in need thereof, comprising:

injecting into or applying in proximity of a physiological target area in proximity to or within a nerve, blood vessel, tumour, or tissue growth of the patient an effective amount of a phenol formulation, the formulation consisting of:

phenol,

a cyclodextrin or derivative thereof complexing at least a portion of the phenol,

at least one pharmacologically acceptable solvent for injection,

at least one dye or other agent to provide for visual localization of the phenol formulation, and

optionally one or more pharmaceutically acceptable excipients.

12. The method according to claim 11 , wherein the phenol formulation comprises from about 3% to about 9% by weight phenol, and from about 10% to about 20% by weight cyclodextrin or derivative.

13. A method for creating a nerve-block in a mammal comprising:

administering an effective amount of a phenol formulation, the formulation consisting of phenol,

a cyclodextrin or derivative thereof complexing at least a portion of the phenol,

at least one pharmacologically acceptable solvent for administration, and

optionally one or more pharmaceutically acceptable excipients; and

further comprising administering at least one dye or other agent to provide for visual localization of the phenol formulation.

14. The method according to claim 13 , wherein the at least one dye or other agent is administered concurrently with the phenol formulation.

15. The method according to claim 13 , wherein the at least one dye or other agent is administered before the phenol formulation.

16. The method according to claim 13 , wherein the at least one dye or other agent is administered after the phenol formulation.

17. The method according to claim 1 , wherein the administering is made into an intra-articular space.

18. The method according to claim 1 , wherein the administering is made into a joint.

19. The method according to claim 1 , wherein the administering is post-surgical.

Continuity (3)
Continuation 16776184 · Jan 29, 2020
Provisional Application 62806188 · Feb 15, 2019
Related Publication 20210145766A1 · May 20, 2021